Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Letters to the Editor
You have accessRestricted Access

Fibroblast Growth Factor-23 Is Not a Single Bystander in Chronic Kidney Disease Mortality

Solenne Pelletier and Denis Fouque
JASN October 2018, 29 (10) 2601; DOI: https://doi.org/10.1681/ASN.2018060583
Solenne Pelletier
Department of Nephrology, Centre Hospitalier Lyon-Sud, Pierre-Benite, Rhone Alpes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Fouque
Department of Nephrology, Centre Hospitalier Lyon-Sud, Pierre-Benite, Rhone Alpes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Denis Fouque
  • Article
  • Info & Metrics
  • View PDF
Loading
  • fibroblast growth factor
  • klotho
  • cardiovascular events
  • hemodialysis
  • survival

We read with great interest the relationship reported by Marthi et al.1 between fibroblast growth factor-23 (FGF-23), morbidity, and mortality in the general population and patients with CKD. The FGF-23 increase has been described in patients with CKD who are unable to clear phosphate from blood, leading to a rapid increase in FGF-23 production and serum concentration. However, FGF-23 does not stand alone in this early metabolic disorder,2 and Klotho, its cofactor, is also a major compound to consider.3

We recently reported two important observations4 on FGF-23/Klotho related to the findings of Marthi et al.1 In a 2-year prospective cohort of 235 patients on maintenance hemodialysis, we found that a serum FGF-23 increase by 10 RU/ml was associated with a 7% greater cardiovascular morbidity and mortality, whereas a serum Klotho above 280 ng/L was associated with a 14% lower event rate. Importantly, these significant associations were independent from each other. Thus, the protection brought by Klotho seems greater than the deleterious FGF-23 effect on cardiovascular events.4 Furthermore, patients with a high Klotho did not present increased morbidity and mortality associated with a high FGF-23. This key information may decipher the pathogenic role of FGF-23 in specific organs.5 FGF-23 may exert its cardiac toxicity only if serum Klotho is reduced, such as has been convincingly shown in an animal model by Hu et al.6 and advocated in our clinical study.4

Thus, the well established association between FGF-23 and mortality is confirmed here by Marthi et al.1 However, analyzing the FGF-23 effect without Klotho data may overemphasize the deleterious effect of FGF-23. It should be interesting to measure Klotho in long-term studies addressing cardiovascular events and FGF23 determination. This may confirm an independent pathogenic FGF23 effect as proposed by Grabner et al.5 or support the absence of causality between high FGF23 and survival suggested by Marthi et al.1

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related Letters to the Editor, “Fibroblast Growth Factor-23 May Follow Cardiovascular Disease Rather than Causing It in Chronic Kidney Disease,” and “Authors’ Reply,” on pages 2602 and 2602–2603, respectively.

  • Copyright © 2018 by the American Society of Nephrology

References

  1. ↵
    1. Marthi A,
    2. Donovan K,
    3. Haynes R,
    4. Wheeler DC,
    5. Baigent C,
    6. Rooney CM, et al
    .: Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: A meta-analysis. J Am Soc Nephrol 29: 579–590, 2018
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Bacchetta J,
    2. Pelletier S
    : Vitamin D deficiency is associated with mortality in maintenance dialysis: Moving forward from epidemiology to clinical trials [published online ahead of print May 22, 2018]. Nephrol Dial Transplant doi:10.1093/ndt/gfy122
    OpenUrlCrossRef
  3. ↵
    1. Kuro-O M
    : Klotho and endocrine fibroblast growth factors: Marker of chronic kidney disease progression and cardiovascular complications [published online ahead of print May 25, 2018]? Nephrol Dial Transplant doi:10.1093/ndt/gfy126
    OpenUrlCrossRef
  4. ↵
    1. Marçais C,
    2. Maucort-Boulch D,
    3. Drai J,
    4. Dantony E,
    5. Carlier MC,
    6. Blond E, et al.: ARNOGENE Project
    : Circulating Klotho associates with cardiovascular morbidity and mortality during hemodialysis. J Clin Endocrinol Metab 102: 3154–3161, 2017pmid:28402487
    OpenUrlPubMed
  5. ↵
    1. Grabner A,
    2. Amaral AP,
    3. Schramm K,
    4. Singh S,
    5. Sloan A,
    6. Yanucil C, et al
    .: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22: 1020–1032, 2015pmid:26437603
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hu MC,
    2. Shi M,
    3. Cho HJ,
    4. Adams-Huet B,
    5. Paek J,
    6. Hill K, et al
    .: Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26: 1290–1302, 2015pmid:25326585
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 29 (10)
Journal of the American Society of Nephrology
Vol. 29, Issue 10
October 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Fibroblast Growth Factor-23 Is Not a Single Bystander in Chronic Kidney Disease Mortality
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fibroblast Growth Factor-23 Is Not a Single Bystander in Chronic Kidney Disease Mortality
Solenne Pelletier, Denis Fouque
JASN Oct 2018, 29 (10) 2601; DOI: 10.1681/ASN.2018060583

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Fibroblast Growth Factor-23 Is Not a Single Bystander in Chronic Kidney Disease Mortality
Solenne Pelletier, Denis Fouque
JASN Oct 2018, 29 (10) 2601; DOI: 10.1681/ASN.2018060583
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients
  • Authors’ Reply: Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients
  • Predicting Kidney Response to Plasma Exchange in ANCA-Associated Vasculitis: Need for Plausible Models
Show more Letters to the Editor

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Fibroblast Growth Factor-23 May Follow Cardiovascular Disease Rather than Causing It in Chronic Kidney Disease
  • Authors’ Reply
  • PubMed
  • Google Scholar

Keywords

  • fibroblast growth factor
  • Klotho
  • cardiovascular events
  • hemodialysis
  • survival

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire